I ran across this comprehensive article about the emergence of new myeloma immunotherapies on OncLive.com over the weekend. It features a who's who of myeloma experts. I'm having some technical difficulties posting the article. Remember Dr. Noopur Raje? She was kind enough to fly down to speak at this year's Pat's Myeloma Beach Party. Dr.
This is complicated stuff. Apparently Amgen, (now own Onyx who makes Kyprolis) is partnering up with others to try and move into the immunotherapy and T cell therapy space. I'm not sure I understand why they need a partner to do this, but money is BIG! Amgen, Xencor to Partner on Cancer Immunotherapy, Inflammation Drugs
I just listened to one of the best and easiest to understand videos I've found, explaining how the new monoclonal antibodies (elotuzumab and daratumumab) work. My good friend and long lived myeloma survivor, Jack Aiello, is interviewing Dana-Farber's Dr. Paul Richardson on a Patient Power broadcast. It's short and to the point. Give it a
As expected, general oncology news is overwhelming myeloma updates at this year's American Society of Clinical Oncology (ASCO) meetings in Chicago. Emerging themes are dominated by success among several immunotherapies and biologics used to battle advanced melanoma (skin cancer), a number of other solid tumor cancer types and soft tissue sarcomas. The overriding mainstream media